The insulin market today is not the market of five years ago. The insulin market of the 2010s was defined by just three drug companies and their brand name products. The lack of competitors meant skyrocketing list prices, increasing once
Medium: Pharmacy Benefit Managers – Providing Lower Prescription Costs for State Medicaid Programs Dealing with COVID-19 June 5, 2020 Given this growing challenge, pharmacy benefit managers (PBMs) have never been more essential. For both public programs and private insurance, PBMs
(Washington, D.C.) — New data from the National Council for Prescription Drug Programs (NCPDP) database, highlighted today by the Pharmaceutical Care Management Association (PCMA), shows that the independent retail pharmacy market in the United States is stable. Over the last 10 years,
Encouraging Signs that the Insulin Affordability Battle is Improving This week, as congressional hearings focus on access to affordable insulins, it should be recognized that a multitude of market forces are working to reduce the cost of insulin products for
New Paper Finds Potential Cost Savings from Adalimumab Biosimilars are Significant but Competitive Market Will Take Time The Pharmaceutical Care Management Association (PCMA) agrees that biosimilars bring more competition to the prescription drug marketplace, which is critical to lowering costs
Economic Analyses Shows “Delinking” Policy Hands Big Pharma a Financial Windfall totaling $32 Billion Annually (Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) issued the following statement on the introduction of H.R. 6283, “Delinking Revenue from Unfair Gouging Act” or
Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion In case you missed it, a new report from The Coalition for Affordable Prescription Drugs (CAPD) and conducted by Matrix Global
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “Ending Pay for PBM Performance: Consequences for Prescription Drug Prices, Utilization, and Government Spending,” authored by University of Chicago Professor of
In case you missed it, a new article in The Atlantic explains how big drug companies commonly use an anti-competitive tactic, “pay-for-delay,” to prevent more affordable options from entering the marketplace.
Study Finds Yearly Cost of Patent Thickets on Five Top-Selling Brand Name Drugs Ranges from $1.8 to $7.6 Billion.
©2024 PCMA. All Rights Reserved.
